SPOTLIGHT -
images
Vibegron improves overactive bladder symptoms in pharmacologically treated BPH
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
Real-world data show high darolutamide use for mHSPC in community urology setting
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Study shows HIFU noninferior to prostatectomy for localized prostate cancer
Treating patients with localized prostate cancer with high-intensity focused ultrasound led to noninferior salvage treatment-free survival vs radical prostatectomy.
Urethral lift is superior to medical therapy in efficacy, patient experience
Patients receiving PUL experienced improvements of 8.6 and (39.1%) and 10 (46.8%) in IPSS total score.